Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: a Pediatric Oncology Group pilot study (9139).

Published

Journal Article

A phase I Pediatric Oncology Group Study was performed combining 7,020 cGy hyperfractionated irradiation (117 cGy twice daily separated by 6 h) with increasing concurrent doses of cisplatin given with the intent of radiosensitization as treatment for children with newly diagnosed brain stem tumors. Cisplatin was infused over 120 h on weeks 1, 3, and 5 during a 6-week radiotherapy course. The following cisplatin dose levels were studied: (1) 50 mg/m2/120 h, (2) 75 mg/m2/120 h and (3) 100 mg/m2/120 h. Sixteen of 17 children completed therapy. One child expired after 2 days of treatment secondary to massive intratumoral hemorrhage. At cisplatin dose level 3 (100 mg/m2/120 h), grade 2-4 myelosuppression was encountered in 3 of 5 evaluable patients. Otherwise, no other excessive toxicities, including renal and ototoxicity, were noted.

Full Text

Duke Authors

Cited Authors

  • Kadota, RP; Mandell, LR; Fontanesi, J; Kovnar, EH; Krischer, J; Kun, LE; Friedman, HS

Published Date

  • 1994

Published In

Volume / Issue

  • 20 / 4

Start / End Page

  • 221 - 225

PubMed ID

  • 8043459

Pubmed Central ID

  • 8043459

International Standard Serial Number (ISSN)

  • 1016-2291

Digital Object Identifier (DOI)

  • 10.1159/000120794

Language

  • eng

Conference Location

  • Switzerland